Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of meibomian gland dysfunction and dry eye~* At least 18 years of age~* Willing to comply with randomization, attend all study visits and follow patient instructions~* Habitual soft contact lens wearer 2 to 18 hours/day and 4 to 7 days/week~* No change in contact lens type or dimensions for the past 3 months~* Clinician assessment of acceptable contact lens fit and disinfecting solution~* Tear film interferometry of 100 units or less~Exclusion Criteria:~* Systemic disease conditions that cause dry eye~* Use of systemic medications known to cause dryness~* History of any of the following ocular conditions in the past 3 months: surgery, trauma, Herpes infection, recurrent inflammation, punctal plug insertion or punctal occlusion~* Presence of any of the following active conditions: ocular infection, ocular inflammation, moderate to severe allergic conjunctivitis, severe eyelid inflammation, eyelid abnormality that affects lid function, or ocular surface abnormality that compromises corneal integrity~* Use of other treatments for meibomian gland dysfunction or dry eye except over the counter lubricants or dietary supplements~* Participation in another ophthalmic drug or device trial in the past month~* Employee, relative of employee or associate of the clinical site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LipiFlow (Type: EXPERIMENTAL): Single 12-minute LipiFlow treatment
- Untreated Control (Type: NO_INTERVENTION): Untreated Control (No Intervention)
- Crossover LipiFlow Treatment (Type: EXPERIMENTAL): Crossover LipiFlow treatment of the untreated control group after 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).